CSF1R inhibitors work by blocking the signaling pathway of the CSF1R, which is involved in the survival, proliferation, and differentiation of monocytes and macrophages. By inhibiting this pathway, these drugs can reduce the number of tumor-associated macrophages (TAMs) in the tumor microenvironment. TAMs often promote tumor growth, metastasis, and resistance to therapy, so their reduction can make the cancer cells more vulnerable to treatment.
